Blood Biomarker p-tau217 Enables Early Prediction of Alzheimer’s Disease Progression
A new blood test biomarker, p-tau217, can predict Alzheimer's disease progression early, offering a noninvasive tool for diagnosis and monitoring, with significant implications for personalized treatment.
A groundbreaking study conducted by researchers at the Sant Pau Research Institute has demonstrated that the plasma biomarker p-tau217, detected through a simple blood test, can effectively predict Alzheimer’s disease progression even at its earliest, pre-symptomatic stages. Published in the journal Neurology, this research underscores the potential of blood-based diagnostics in diagnosing and monitoring neurodegenerative conditions.
The study involved 731 participants, both with and without cognitive impairment, who were followed over an average of ten years. By analyzing levels of p-tau217—a specific form of the tau protein linked to neurodegeneration—the researchers found that this biomarker not only correlates with the presence of Alzheimer’s but also forecasts the speed of cognitive decline and the transition to dementia.
Dr. Ignacio Illán, the lead researcher, emphasized the significance of this marker: "p-tau217 can identify individuals at risk before symptoms manifest and help estimate disease progression, which is vital for clinical decision-making." Similarly, neuropsychologist Judit Selma-González highlighted its utility in selecting suitable candidates for clinical trials of disease-modifying therapies.
Traditionally, diagnosing Alzheimer’s required invasive procedures like lumbar punctures or expensive imaging techniques such as PET scans. The use of plasma p-tau217 offers a noninvasive, cost-effective alternative, with levels increasing progressively from preclinical to advanced stages of the disease. It even outperformed its cerebrospinal fluid counterpart, p-tau181, in prognostic accuracy.
This advancement holds substantial promise in the era where disease-modifying treatments—like anti-amyloid antibodies—are becoming available, with their use contingent on disease stage. A simple blood test could soon enable clinicians to determine disease stage and monitor progression more effectively, facilitating personalized medicine approaches.
In conclusion, blood-based biomarkers like p-tau217 could revolutionize the early detection and management of Alzheimer’s disease, making diagnosis more accessible and improving treatment outcomes.
Source: https://medicalxpress.com/news/2025-07-blood-biomarker-alzheimer-disease-earliest.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Enhancing Trauma-Informed Care in Pediatric Medical Procedures
Advocates are calling for increased use of trauma-informed care in pediatric medical procedures to reduce emotional harm and improve children's healthcare experiences. Learn how strategies like honest communication and distraction techniques can replace restraint practices.
Biomedical Engineering Students Innovate to Address Safety Challenges in Sports and Daily Life
Biomedical engineering students at the University of Cincinnati are developing innovative solutions to prevent and repair injuries in sports and everyday life, focusing on concussion prevention, safer gear, and neonatal safety.
Different Types of Hormone Therapy Affect Memory in Postmenopausal Women, Study Shows
A new study reveals that the type of estradiol-based hormone therapy used during menopause can influence different types of memory in women, highlighting the importance of personalized hormone treatment for brain health.
